{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:55:31Z","timestamp":1775861731440,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":722,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 59-year-old woman with schizoaffective disorder presented with an itchy, blistering generalised rash. One month prior, she had started empagliflozin, a sodium glucose transporter-2 (SGLT-2) inhibitor, used in type-2-diabetes. She was already established on paliperidone, an atypical antipsychotic, for 1 year. Serology at presentation was positive for anti-pemphigoid antibodies. Histology demonstrated subepidermal blistering, perivascular inflammation and eosinophils. Direct immunofluorescence was characteristic of bullous pemphigoid (BP), with linear IgG and C3 at the basement membrane. Both empagliflozin and paliperidone were discontinued. However, the blisters persisted. Treatment included: topical Dermovate and Eumovate ointment for the body and face respectively, alongside oral doxycycline 200 mg and prednisolone 40 mg for a week (reducing by 5 mg\/week over 8 weeks). Nevertheless, new blisters continued developing, hence dapsone 50 mg was introduced, with significant improvement. Increasingly, several neurological and psychiatric disorders have been linked with BP, complicating aetiology and management. The underlying mechanism for these associations is not fully understood. Bullous pemphigoid autoantigens BP180 and BP230 are expressed in the central nervous system and it is thought that neurodegeneration may expose antigens to the immune system, generating a cross-reactive immune response. However, there also appears to be bidirectional causality between BP and neuropsychological conditions. Furthermore, as there was an association of empagliflozin initiation and BP onset, this further complicates the aetiology and presents a potential novel drug cause of BP. This case emphasises the neuropsychological issues associated with managing complex BP cases, a possible novel cause of drug-induced BP and highlights the likelihood of these issues becoming increasingly prevalent for the future.<\/jats:p>","DOI":"10.1002\/ski2.176","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T06:39:45Z","timestamp":1666420785000},"source":"Crossref","is-referenced-by-count":7,"title":["Bullous Pemphigoid in a Patient with a Neuropsychological Disorder and a Possible Novel Drug Trigger: A Case Report and Review of the Literature"],"prefix":"10.1093","volume":"2","author":[{"given":"Sarah M.","family":"Dyson","sequence":"first","affiliation":[{"name":"Dermatology Department, Norfolk and Norwich University Hospital , Colney ,","place":["UK"]},{"name":"Norwich Medical School, UEA , Norwich ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya U.","family":"Patel","sequence":"additional","affiliation":[{"name":"Dermatology Department, Norfolk and Norwich University Hospital , Colney ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Igali","sequence":"additional","affiliation":[{"name":"Cellular Pathology Department, Norfolk and Norwich University Hospital , Colney ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-2085","authenticated-orcid":false,"given":"George W. M.","family":"Millington","sequence":"additional","affiliation":[{"name":"Dermatology Department, Norfolk and Norwich University Hospital , Colney ,","place":["UK"]},{"name":"Norwich Medical School, UEA , Norwich ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"1","key":"2025010818060092500_ski2176-bib-0001","doi-asserted-by":"publisher","DOI":"10.1038\/srep37125","article-title":"Psychiatric and neurological disorders are associated with bullous pemphigoid - a nationwide Finnish Care Register study","volume":"6","author":"F\u00f6rsti","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"2025010818060092500_ski2176-bib-0002","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid\u2014more than skin deep?","volume":"26","author":"F\u00f6rsti","year":"2017","journal-title":"Exp Dermatol"},{"key":"2025010818060092500_ski2176-bib-0003","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12144-021-01396-1","article-title":"Anxiety and depression predispose individuals to an autoimmune bullous diseases-bullous pemphigoid: a large-scale population-based cohort study","author":"Kridin","year":"2021","journal-title":"Curr Psychol"},{"issue":"6","key":"2025010818060092500_ski2176-bib-0004","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1440-1819.2011.02260.x","article-title":"Psychiatric complications of treatment with corticosteroids: review with case report","volume":"65","author":"Kenna","year":"2011","journal-title":"Psychiatr Clin Neurosci"},{"issue":"10","key":"2025010818060092500_ski2176-bib-0005","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1111\/jdv.17600","article-title":"An integrated approach is recommended in bullous pemphigoid","volume":"35","author":"Poot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2025010818060092500_ski2176-bib-0006","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12888-020-02810-x","article-title":"Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers","volume":"20","author":"Rania","year":"2020","journal-title":"BMC Psychiatr"},{"issue":"3","key":"2025010818060092500_ski2176-bib-0007","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"12","key":"2025010818060092500_ski2176-bib-0008","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"2025010818060092500_ski2176-bib-0009","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/jdv.17304","article-title":"Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti-BP230 seropositivity","volume":"35","author":"St\u00e4nder","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2025010818060092500_ski2176-bib-0010","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jid.2016.09.010","article-title":"Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer\u2019s disease","volume":"137","author":"Kokkonen","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2025010818060092500_ski2176-bib-0011","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"J Am Med Assoc Dermatol"},{"issue":"1","key":"2025010818060092500_ski2176-bib-0012","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaad.2019.02.017","article-title":"Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: a case-control study","volume":"81","author":"Varpuluoma","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025010818060092500_ski2176-bib-0013","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ccid.s212984","article-title":"Depression and anxiety in patients with bullous pemphigoid: impact and management challenges","volume":"13","author":"Kluger","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10079","key":"2025010818060092500_ski2176-bib-0014","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"2025010818060092500_ski2176-bib-0015","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/12640-020-00268-z","article-title":"Effects of doxycycline in Swiss mice predictive models of schizophrenia","volume":"38","author":"Issy","year":"2020","journal-title":"Neurotox Res"},{"issue":"2","key":"2025010818060092500_ski2176-bib-0016","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaad.2018.09.048","article-title":"Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis","volume":"85","author":"Kridin","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2025010818060092500_ski2176-bib-0017","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.jid.2021.05.015","article-title":"GLP-1 analogs and SGLT2 inhibitors do not increase risk of bullous pemphigoid","volume":"141","author":"Varpuluoma","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2025010818060092500_ski2176-bib-0018","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/jdv.18106","article-title":"Association between sodium-glucose co-transporter 2 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a nationwide population-based cohort study","volume":"36","author":"Ma","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"2025010818060092500_ski2176-bib-0019","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14740338.2020.1782884","article-title":"Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials","volume":"19","author":"Watada","year":"2020","journal-title":"Expet Opin Drug Saf"},{"issue":"2","key":"2025010818060092500_ski2176-bib-0020","first-page":"59","article-title":"A case of bullous pemphigoid associated with the administration of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor","volume":"61","author":"Ikehara","year":"2018","journal-title":"J Jpn Diabetes Soc"},{"key":"2025010818060092500_ski2176-bib-0021","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"2025010818060092500_ski2176-bib-0022","author":"Medicines and Healthcare products Regulatory Agency","journal-title":"Yellow card scheme"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ski2.176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ski2.176","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/2\/4\/ski2.176\/59728722\/skinhd_2_4_e176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/2\/4\/ski2.176\/59728722\/skinhd_2_4_e176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:06:08Z","timestamp":1736359568000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.176\/7750811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.176","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,10,21]]},"article-number":"ski2.176"}}